{"title":"戈谢病:单基因疾病的多重教训。","authors":"Ernest Beutler","doi":"10.1080/08035320600619039","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong>Gaucher disease is the most common lysosomal storage disease. It is caused by a deficiency in the lysosomal enzyme glucocerebrosidase, a beta-glucosidase, which results in the accumulation of the lipid glucocerebroside in macrophages throughout the body. Gaucher disease is most common in the Ashkenazi Jewish population, and three mutations of the gene encoding glucocerebrosidase (GBA) have been shown to be prevalent in this population (c.1226 A > C [N370S], 84GG and IVS2[+1]). In non-Jewish patients, the most common mutation is c.1448 G > C (L444P). Until 15 years ago, treatment has been restricted to symptomatic interventions, such as splenectomy or hip replacement. However, there are now specific treatment options - enzyme replacement therapy and substrate reduction therapy. Future developments may include the use of chaperone therapy.</p><p><strong>Conclusion: </strong>The lessons that we have learned from Gaucher disease may well be applicable to the development of therapies for some of the other less common lysosomal storage diseases.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 451","pages":"103-9"},"PeriodicalIF":0.0000,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600619039","citationCount":"68","resultStr":"{\"title\":\"Gaucher disease: multiple lessons from a single gene disorder.\",\"authors\":\"Ernest Beutler\",\"doi\":\"10.1080/08035320600619039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Unlabelled: </strong>Gaucher disease is the most common lysosomal storage disease. It is caused by a deficiency in the lysosomal enzyme glucocerebrosidase, a beta-glucosidase, which results in the accumulation of the lipid glucocerebroside in macrophages throughout the body. Gaucher disease is most common in the Ashkenazi Jewish population, and three mutations of the gene encoding glucocerebrosidase (GBA) have been shown to be prevalent in this population (c.1226 A > C [N370S], 84GG and IVS2[+1]). In non-Jewish patients, the most common mutation is c.1448 G > C (L444P). Until 15 years ago, treatment has been restricted to symptomatic interventions, such as splenectomy or hip replacement. However, there are now specific treatment options - enzyme replacement therapy and substrate reduction therapy. Future developments may include the use of chaperone therapy.</p><p><strong>Conclusion: </strong>The lessons that we have learned from Gaucher disease may well be applicable to the development of therapies for some of the other less common lysosomal storage diseases.</p>\",\"PeriodicalId\":76973,\"journal\":{\"name\":\"Acta paediatrica (Oslo, Norway : 1992). Supplement\",\"volume\":\"95 451\",\"pages\":\"103-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/08035320600619039\",\"citationCount\":\"68\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta paediatrica (Oslo, Norway : 1992). Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/08035320600619039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta paediatrica (Oslo, Norway : 1992). Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08035320600619039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 68
摘要
未标示:戈谢病是最常见的溶酶体贮积病。它是由溶酶体葡萄糖脑苷酶(一种β -葡萄糖苷酶)缺乏引起的,导致脂质糖脑苷在全身巨噬细胞中积累。戈谢病在德系犹太人人群中最为常见,编码葡萄糖脑苷酶(GBA)基因的三种突变已被证明在该人群中普遍存在(c.1226)A > C [N370S], 84GG和IVS2[+1])。在非犹太患者中,最常见的突变是c.1448G > c (l444p)。直到15年前,治疗一直局限于对症干预,如脾切除术或髋关节置换术。然而,现在有特定的治疗选择——酶替代疗法和底物还原疗法。未来的发展可能包括伴侣疗法的使用。结论:我们从戈谢病中吸取的经验教训很可能适用于其他一些不常见的溶酶体贮积病的治疗方法的开发。
Gaucher disease: multiple lessons from a single gene disorder.
Unlabelled: Gaucher disease is the most common lysosomal storage disease. It is caused by a deficiency in the lysosomal enzyme glucocerebrosidase, a beta-glucosidase, which results in the accumulation of the lipid glucocerebroside in macrophages throughout the body. Gaucher disease is most common in the Ashkenazi Jewish population, and three mutations of the gene encoding glucocerebrosidase (GBA) have been shown to be prevalent in this population (c.1226 A > C [N370S], 84GG and IVS2[+1]). In non-Jewish patients, the most common mutation is c.1448 G > C (L444P). Until 15 years ago, treatment has been restricted to symptomatic interventions, such as splenectomy or hip replacement. However, there are now specific treatment options - enzyme replacement therapy and substrate reduction therapy. Future developments may include the use of chaperone therapy.
Conclusion: The lessons that we have learned from Gaucher disease may well be applicable to the development of therapies for some of the other less common lysosomal storage diseases.